AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|AAPL308.63+14.25 (+4.84%) ▲|ABBV261.07+10.01 (+3.99%) ▲|ABT95.40+3.22 (+3.49%) ▲|ACN137.35+6.22 (+4.74%) ▲|ADBE219.72+8.74 (+4.14%) ▲|AMAT603.04-47.87 (-7.35%) ▼|AMD517.82-23.06 (-4.26%) ▼|AMGN374.15+12.82 (+3.55%) ▲|AMT166.03-0.05 (-0.03%) ▼|AMZN242.67+0.97 (+0.40%) ▲|AVGO360.45-8.89 (-2.41%) ▼|AXP351.96+4.91 (+1.41%) ▲|BA226.49+7.91 (+3.62%) ▲|BAC58.73+0.37 (+0.63%) ▲|BKNG184.56+1.92 (+1.05%) ▲|BLK995.73+15.35 (+1.57%) ▲|BMY58.13+2.32 (+4.16%) ▲|BNY146.62+0.60 (+0.41%) ▲|BRK-B507.78+8.04 (+1.61%) ▲|C139.97-0.16 (-0.11%) ▼|CAT963.53-27.88 (-2.81%) ▼|CL95.13+2.37 (+2.56%) ▲|CMCSA23.79+0.06 (+0.25%) ▲|COF205.12+0.30 (+0.15%) ▲|COP104.73+1.51 (+1.46%) ▲|COST951.67+27.00 (+2.92%) ▲|CRM166.11+2.88 (+1.76%) ▲|CSCO112.69-4.32 (-3.69%) ▼|CVS104.72-0.09 (-0.09%) ▼|CVX169.20+3.51 (+2.12%) ▲|DE621.27-6.36 (-1.01%) ▼|DHR197.93+4.21 (+2.17%) ▲|DIS99.50+3.79 (+3.96%) ▲|DUK129.60+3.83 (+3.05%) ▲|EMR139.05-0.47 (-0.34%) ▼|FDX313.00-0.89 (-0.28%) ▼|GD373.54+12.27 (+3.40%) ▲|GE377.52+2.58 (+0.69%) ▲|GEV1,113.11-21.24 (-1.87%) ▼|GILD131.27+5.30 (+4.21%) ▲|GM76.00+0.48 (+0.64%) ▲|GOOG356.18-1.71 (-0.48%) ▼|GOOGL359.91-1.30 (-0.36%) ▼|GS1,021.00+1.39 (+0.14%) ▲|HD357.90+7.06 (+2.01%) ▲|HON229.86+8.11 (+3.66%) ▲|IBM289.52+3.27 (+1.14%) ▲|INTC120.35-6.67 (-5.25%) ▼|INTU275.35+8.27 (+3.10%) ▲|ISRG426.01+23.63 (+5.87%) ▲|JNJ263.04+9.06 (+3.57%) ▲|JPM334.47+0.40 (+0.12%) ▲|KO84.14+2.85 (+3.51%) ▲|LIN546.64+13.09 (+2.45%) ▲|LLY1,213.91+22.17 (+1.86%) ▲|LMT545.91+24.09 (+4.62%) ▲|LOW227.50+5.58 (+2.51%) ▲|LRCX351.41-39.85 (-10.19%) ▼|MA539.39+16.95 (+3.24%) ▲|MCD280.63+11.20 (+4.16%) ▲|MDLZ60.91+1.56 (+2.63%) ▲|MDT83.19+3.99 (+5.04%) ▲|META582.90-30.01 (-4.90%) ▼|MMM160.44+0.48 (+0.30%) ▲|MO72.71+1.17 (+1.64%) ▲|MRK129.56+4.19 (+3.34%) ▲|MS213.93+2.07 (+0.98%) ▲|MSFT390.49+6.21 (+1.62%) ▲|MU975.56-56.72 (-5.49%) ▼|NEE88.34+1.97 (+2.28%) ▲|NFLX77.65+3.46 (+4.66%) ▲|NKE44.09+1.03 (+2.39%) ▲|NOW106.32+0.52 (+0.49%) ▲|NVDA194.83-2.75 (-1.39%) ▼|ORCL140.27-2.23 (-1.56%) ▼|PEP144.22+3.06 (+2.17%) ▲|PFE24.32+0.44 (+1.84%) ▲|PG151.41+3.98 (+2.70%) ▲|PLTR129.30+3.57 (+2.84%) ▲|PM182.27+4.58 (+2.58%) ▲|QCOM176.25-5.67 (-3.12%) ▼|RTX199.25+7.47 (+3.90%) ▲|SBUX104.27+0.88 (+0.85%) ▲|SCHW97.00+1.22 (+1.27%) ▲|SO97.98+2.86 (+3.01%) ▲|SPG226.06+3.06 (+1.37%) ▲|T20.58+0.10 (+0.49%) ▲|TMO523.44+10.11 (+1.97%) ▲|TMUS177.52+4.46 (+2.58%) ▲|TSLA393.45-31.85 (-7.49%) ▼|TXN293.08-5.33 (-1.79%) ▼|UBER74.43+1.77 (+2.44%) ▲|UNH425.36-1.18 (-0.28%) ▼|UNP282.25+4.52 (+1.63%) ▲|UPS110.66+1.12 (+1.02%) ▲|USB61.73-0.23 (-0.37%) ▼|V362.13+11.05 (+3.15%) ▲|VZ42.56+0.57 (+1.36%) ▲|WFC85.51-0.43 (-0.50%) ▼|WMT111.84+3.02 (+2.78%) ▲|XOM137.09+0.81 (+0.59%) ▲|
25.5 C
New York
Monday, July 6, 2026

Tag: litigation

newssourceFORcompanyinformationcontent1releasesmarket

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

BAB, Inc. Announces Cash Distribution

DEERFIELD, Ill, June 06, 2025 (GLOBE NEWSWIRE) -- BAB, Inc. (OTCQB: BABB), today announced that its Board of Directors has declared a quarterly distribution of one cent ($0.01) per share, payable on July 14, 2025 to shareholders of record as of June 26, 2025.

CAR Investors Have Opportunity to Lead Avis Budget Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, June 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Avis...

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

Willis Lease Finance Corporation Announces Pricing of $596.0 Million in Fixed Rate Notes

COCONUT CREEK, Fla., June 06, 2025 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”), the leading lessor of commercial aircraft engines and global provider of aviation services, announced today that its wholly-owned subsidiary, Willis Engine Structured Trust VIII (“WEST”), has priced $524,000,000 in aggregate principal amount of Series A Fixed Rate Notes (the “Series A Notes”) and $72,000,000 in aggregate principal amount of Series B Fixed Rate Notes (the “Series B Notes” and, together with the Series A Notes, the “Notes”). The Notes will be secured by, among other things, WEST’s direct and indirect interests in a portfolio of 62 aircraft engines and two airframes, which WEST will acquire from WLFC or its other subsidiaries pursuant to an asset purchase agreement. The planned closing date is June 18, 2025. 

Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors

HAMPTON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Denice M. Torres has been elected to the company’s Board of Directors.

SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR JUNE 2025

DALLAS, June 6, 2025 /PRNewswire/ -- Argent Trust Company, as Trustee of the Sabine Royalty Trust (NYSE: SBR), today declared a cash distribution to the...

DeFi Dev Corp. Partners with Drift Protocol to List dfdvSOL Liquid Staking Token

BOCA RATON, FL, June 06, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a strategic partnership with Drift Protocol, the leading decentralized derivatives exchange on Solana with $1B in deposits.

Neo Performance Materials Announces Normal Course Issuer Bid and Automatic Purchase Plan for its Common Shares, and Commences Trading on the OTCQX Market

TORONTO, June 6, 2025 /CNW/ - Neo Performance Materials Inc. ("Neo" or the "Company") (TSX: NEO) announced the Toronto Stock Exchange (the "TSX") has...

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –

Ferrellgas Partners, L.P. Reports Third Quarter Fiscal Year 2025 Results

LIBERTY, Mo., June 06, 2025 (GLOBE NEWSWIRE) -- Ferrellgas Partners, L.P. (OTC: FGPR) (“Ferrellgas” or the “Company”) today reported financial results for its 2025 third fiscal quarter ended April 30, 2025.

AKEEGA® (niraparib e abiraterone acetato): la compressa a doppia azione di Johnson & Johnson è la prima combinazione di PARP inibitori a mostrare una...

I risultati dello studio di Fase 3 AMPLITUDE mettono in luce il potenziale di niraparib e abiraterone acetato nel ritardare la progressione del cancro e il peggioramento dei sintomi1

Burning Rock Reports First Quarter 2025 Financial Results

Burning Rock Reports First Quarter 2025 Financial Results

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

TAIPEI, Taiwan, June 06, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174. TWO), and TegMine Therapeutics, Inc. (TegMine), a US Biopharma specialized in developing best-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related Master Services Agreement (MSA).

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLitigation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers